Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors. (October 2020) - Janku, F.; Abdul-Karim, R.; Azad, A.; Bendell, J.; Gan, H.; Sen, S.; Tan, T.; Wang, J.; Marina, N.; Baker, L.; Ma, L.; Mooney, J.; et al.